Ledger.Open graph →
SEC Form D · Amendment · filed July 25, 2017

Fulcrum Therapeutics, Inc

Offering
$55.0M
Sold
$29.7M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (9)

Matthew W. Kaplan · New York, NYExec · DirectorPatrick Whalen · Millville, DEDirectorSharon Berberich · St. Louis, MODirectorJennifer W. Cattier · New York, NYDirectorRichard R. Gilliam · Vancouver, British Columbia, CanadaDirectorPaddy Dear · Grand Cayman, Cayman IslandsExec · DirectorReade Griffith · Grand Cayman, Cayman IslandsDirectorDavid Chase · Seattle, WADirectorMelissa Taylor · Seattle, WADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗